Oppenheimer Asset Management Inc. Has $352,000 Stake in Grifols, S.A. (NASDAQ:GRFS)

Oppenheimer Asset Management Inc. boosted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 56.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,887 shares of the biotechnology company’s stock after buying an additional 20,120 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Grifols were worth $352,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Grifols during the 4th quarter valued at about $26,137,000. Capital World Investors boosted its holdings in Grifols by 4.9% during the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock valued at $138,605,000 after purchasing an additional 961,700 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Grifols by 6.9% in the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock valued at $54,156,000 after purchasing an additional 302,380 shares during the period. Anthracite Investment Company Inc. acquired a new position in shares of Grifols in the 1st quarter worth approximately $1,970,000. Finally, Hantz Financial Services Inc. bought a new position in shares of Grifols during the 2nd quarter worth approximately $1,235,000.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $8.95 on Friday. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. The business’s fifty day moving average price is $8.17 and its two-hundred day moving average price is $7.34. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15.

Grifols (NASDAQ:GRFS) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. Sell-side analysts anticipate that Grifols, S.A. will post 0.79 earnings per share for the current year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.